NEUROCRINE BIOSCIENCES INC Insider Trading for February 2016
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NEUROCRINE BIOSCIENCES INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in NEUROCRINE BIOSCIENCES INC for February 2016.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 12 2016 | NBIX | NEUROCRINE BIOSCIE ... | MOLLICA JOSEPH A | Director | Option Exercise | M | 3.07 | 20,000 | 61,400 | 0 | |
| Feb 12 2016 | NBIX | NEUROCRINE BIOSCIE ... | MOLLICA JOSEPH A | Director | Payment of Exercise | F | 33.70 | 1,821 | 61,368 | 37,354 | 39.2 K to 37.4 K (-4.65 %) |
| Feb 12 2016 | NBIX | NEUROCRINE BIOSCIE ... | MOLLICA JOSEPH A | Director | Buy | M | 3.07 | 20,000 | 61,400 | 39,175 | 19.2 K to 39.2 K (+104.30 %) |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | OBrien Christopher Flint | Chief Medical Offic ... | Option Exercise | A | 0.00 | 30,500 | 0 | 30,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | OBrien Christopher Flint | Chief Medical Offic ... | Option Exercise | A | 35.99 | 60,600 | 2,180,994 | 60,600 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | OBrien Christopher Flint | Chief Medical Offic ... | Option Exercise | A | 0.00 | 12,800 | 0 | 12,800 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 35.99 | 36,400 | 1,310,036 | 36,400 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lloyd-Smith Malcolm | Chief Regulatory Of ... | Option Exercise | A | 0.00 | 7,700 | 0 | 7,700 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lippoldt Darin | Chief Legal Officer | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lippoldt Darin | Chief Legal Officer | Option Exercise | A | 35.99 | 41,200 | 1,482,788 | 41,200 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Lippoldt Darin | Chief Legal Officer | Option Exercise | A | 0.00 | 8,700 | 0 | 8,700 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Grigoriadis Dimitri E. | Chief Research Offi ... | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Grigoriadis Dimitri E. | Chief Research Offi ... | Option Exercise | A | 35.99 | 36,400 | 1,310,036 | 36,400 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Grigoriadis Dimitri E. | Chief Research Offi ... | Option Exercise | A | 0.00 | 7,700 | 0 | 7,700 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Option Exercise | A | 0.00 | 35,750 | 0 | 35,750 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Option Exercise | A | 35.99 | 109,100 | 3,926,509 | 109,100 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Option Exercise | A | 0.00 | 23,000 | 0 | 23,000 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 35.99 | 36,400 | 1,310,036 | 36,400 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Option Exercise | A | 0.00 | 7,700 | 0 | 7,700 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Coughlin Timothy P | Chief Financial Off ... | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Coughlin Timothy P | Chief Financial Off ... | Option Exercise | A | 35.99 | 48,500 | 1,745,515 | 48,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Coughlin Timothy P | Chief Financial Off ... | Option Exercise | A | 0.00 | 10,200 | 0 | 10,200 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Bozigian Haig P. | Chief Development O ... | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Bozigian Haig P. | Chief Development O ... | Option Exercise | A | 35.99 | 48,500 | 1,745,515 | 48,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | Bozigian Haig P. | Chief Development O ... | Option Exercise | A | 0.00 | 10,200 | 0 | 10,200 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 35.99 | 41,200 | 1,482,788 | 41,200 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 8,700 | 0 | 8,700 | |
| Feb 04 2016 | NBIX | NEUROCRINE BIOSCIE ... | OBrien Christopher Flint | Chief Medical Offic ... | Sell | S | 38.01 | 1,500 | 57,015 | 130,044 | 131.5 K to 130 K (-1.14 %) |
| Feb 04 2016 | NBIX | NEUROCRINE BIOSCIE ... | Grigoriadis Dimitri E. | Chief Research Offi ... | Sell | S | 37.98 | 1,375 | 52,223 | 109,933 | 111.3 K to 109.9 K (-1.24 %) |
| Feb 04 2016 | NBIX | NEUROCRINE BIOSCIE ... | GORMAN KEVIN CHARLES | President and CEO | Sell | S | 38.04 | 3,125 | 118,875 | 228,077 | 231.2 K to 228.1 K (-1.35 %) |
| Feb 04 2016 | NBIX | NEUROCRINE BIOSCIE ... | Gano Kyle | Chief Business Deve ... | Sell | S | 37.98 | 1,375 | 52,223 | 55,863 | 57.2 K to 55.9 K (-2.40 %) |
| Feb 04 2016 | NBIX | NEUROCRINE BIOSCIE ... | Coughlin Timothy P | Chief Financial Off ... | Sell | S | 38.06 | 1,500 | 57,090 | 131,374 | 132.9 K to 131.4 K (-1.13 %) |
| Feb 04 2016 | NBIX | NEUROCRINE BIOSCIE ... | Bozigian Haig P. | Chief Development O ... | Sell | S | 38.13 | 1,375 | 52,429 | 111,454 | 112.8 K to 111.5 K (-1.22 %) |